Physician profile
David L Baker
NPI 1811015845
$2,957.19
in general payments reported to CMS, 2019-2025
35 companies · $903 in 2025
The $903 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $225 · 2021: $323 · 2022: $179 · 2023: $464 · 2024: $460 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.01 | 2021-2025 | Qulipta, Botox |
| Lundbeck LLC | $319.53 | 2023-2025 | Vyepti |
| Livanova USA, INC. | $268.14 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Scilex Pharmaceuticals INC. | $207.88 | 2019-2024 | Ztlido |
| Medtronic, INC. | $207.60 | 2021-2025 | Midas Rex, Plasmablade(Tm), Aquamantys(Tm) |
| Collegium Pharmaceutical, INC. | $167.39 | 2019-2023 | Belbuca |
| Amgen INC. | $128.94 | 2019-2021 | |
| Pfizer INC. | $101.45 | 2021-2024 | |
| Nevro Corp. | $96.81 | 2024 | Senza |
| Arbor Pharmaceuticals, INC. | $92.97 | 2019-2022 | |
| Boston Scientific Corporation | $91.72 | 2023 | |
| Novartis Pharmaceuticals Corporation | $88.88 | 2019-2021 | |
| Abbott Laboratories | $83.88 | 2022-2025 | Eterna |
| Supernus Pharmaceuticals, INC. | $76.01 | 2019-2021 | |
| Argenx US, INC. | $72.57 | 2025 | Vyvgart Hytrulo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.33 | 2019-2021 | |
| Averitas Pharma INC. | $53.64 | 2025 | Qutenza |
| Ibsa Pharma INC. | $40.56 | 2021-2023 | Tirosint, Licart |
| Lilly USA, LLC | $38.46 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.63 | 2019 | |
| Merz North America, INC. | $35.43 | 2019 | |
| Merz Pharmaceuticals, LLC | $32.92 | 2024 | Xeomin |
| Biodelivery Sciences International, INC. | $31.37 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.84 | 2025 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $29.74 | 2023-2024 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.52 | 2019 | |
| Ucb, INC. | $25.77 | 2025 | Zilbrysq |
| Avanos Medical | $24.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.31 | 2019 | |
| Forte Bio-Pharma LLC | $23.28 | 2020 | |
| Bausch Health US, LLC | $20.64 | 2019 | |
| Zimmer Biomet Holdings, INC. | $18.96 | 2025 | Thinflap |
| Horizon Therapeutics Plc | $17.13 | 2019 | |
| Protega Pharmaceutials INC | $14.06 | 2023 | Roxybond |
| Portola Pharmaceuticals, LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.